News

Apexian Pharmaceuticals licenses IU discoveries

INDIANAPOLIS, IN-- Apexian Pharmaceuticals Inc., a biotechnology company focused on developing novel compounds to treat cancer, has licensed all technology discovered in Mark Kelley's laboratory at the Indiana University School of Medicine. Read story on Indiana University website Indiana University Research and Technology Corp., which protects, markets and licenses intellectual property developed at IU so it can be commercialized by industry, issued the license. It allows...

Kelley presented Bantz-Petrinio Research award

Mark R. Kelley, PhD, was awarded the 2017 Bantz-Petronio Translating Research into Practice Award in recognition of his exemplary translational research in the area of cancer. In 2013 Former Chancellor Charles Bantz and Dr. Sandra Petronio established the Bantz-Petronio Translating Research into Practice Award because translational work is core to the schools of IUPUI. The award recognizes outstanding faculty research that is interdisciplinary and/or cross-disciplinary,...

Kelley, IU researchers awarded $2.9 million to study chemotherapy-induced peripheral neuropathy

Indiana University cancer researchers have been awarded $2.9 million to study the debilitating side effects caused by chemotherapy that affect a significant number of cancer patients. Mark R. Kelley, PhD, received the grant (1R01CA205166) from the National Cancer Institute to study chemotherapy-induced peripheral neuropathy (CIPN). Although cancer treatments are becoming more effective and people are consequently surviving cancer in increasing rates, many patients report neuropathy...